Free tool
Cell therapy stocks
We cover 47 companies grouped under the Cell therapy theme. The median market value in the group is $34.67M. Across the group, the median move over the past trading day is 0.00%. 26% of the 47 with a 200-day average trade above it. Price change over the past year runs from −85.5% to +3.8% across the middle 80 percent of the group, with a median of −38.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
47 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | −3.82% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% |
| VCEL | Vericel Corporation | $2.21B | Mid cap | +20.76% |
| ATRA | Atara Biotherapeutics, Inc. | $98.77M | Micro cap | −19.61% |
| ACET | Adicet Bio, Inc. | $84.25M | Micro cap | −20.89% |
| INKT | MiNK Therapeutics, Inc. | $60.32M | Micro cap | −21.89% |
| V3V.DE | FamiCord AG | $58.21M | Micro cap | −60.69% |
| 7776.T | CellSeed Inc. | $56.74M | Micro cap | −47.42% |
| 4896.T | K Pharma,Inc. | $56.45M | Micro cap | +15.89% |
| 4584.T | Kidswell Bio Corporation | $55.83M | Micro cap | −24.37% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $53.78M | Micro cap | +81.25% |
| ALA.AX | Arovella Therapeutics Limited | $52.84M | Micro cap | −26.19% |
| TCRX | TScan Therapeutics, Inc. | $51.87M | Micro cap | −58.23% |
| 7096.T | StemCell Institute Inc. | $48.78M | Micro cap | −21.54% |
| TVGN | Tevogen Inc. | $44.34M | Micro cap | −84.85% |
| 2370.T | MEDINET Co., Ltd. | $44.25M | Micro cap | −34.21% |
| 3750.T | ADR Biomedical Holdings Inc. | $43.59M | Micro cap | −15.61% |
| 4880.T | CellSource Co., Ltd. | $43.15M | Micro cap | −41.78% |
| 4893.T | Noile-Immune Biotech Inc. | $40.36M | Micro cap | −17.32% |
| PTG.WA | Poltreg S.A. | $36.84M | Micro cap | −16.00% |
| 4892.T | Cyfuse Biomedical K.K. | $36.02M | Micro cap | −9.22% |
| CCEL | Cryo-Cell International, Inc. | $34.67M | Micro cap | −0.92% |
| ESLA | Estrella Immunopharma, Inc. | $31.97M | Micro cap | −24.41% |
| SVA.TO | Sernova Biotherapeutics Inc | $30.03M | Micro cap | −38.89% |
| PSH0.DE | Sernova Biotherapeutics Inc | $26.97M | Micro cap | −46.78% |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −12.71% |
| 311A.T | NPT Co Ltd | $20.81M | Micro cap | −43.33% |
| NCEL | NewcelX Ltd. | $19.83M | Micro cap | −85.80% |
| PLUR | Pluri Inc. | $17.91M | Micro cap | −71.43% |
| BCDA | BioCardia, Inc. | $17.11M | Micro cap | −42.05% |
| SNTI | Senti Biosciences Holdings, Inc. | $12.17M | Micro cap | −75.42% |
| F98.F | CytoMed Therapeutics Limited | $11.54M | Micro cap | −54.82% |
| INAB | IN8bio, Inc. | $11.53M | Micro cap | −46.58% |
| GDTC | CytoMed Therapeutics Limited | $11.06M | Micro cap | −52.59% |
| FBLG | FibroBiologics, Inc. | $9.32M | Micro cap | −88.54% |
| CMB.AX | Cambium Bio Limited | $8.86M | Micro cap | 0.00% |
| CELZ | Creative Medical Technology Holdings, Inc. | $7.98M | Micro cap | −61.19% |
| 1AD.AX | AdAlta Limited | $6.90M | Micro cap | −12.50% |
| ERNA | Ernexa Therapeutics Inc. | $5.87M | Micro cap | −86.22% |
| PMCB | PharmaCyte Biotech, Inc. | $5.79M | Micro cap | −48.78% |
| BRTX | BioRestorative Therapies, Inc. | $5.67M | Micro cap | −85.26% |
| MBIO | Mustang Bio, Inc. | $4.18M | Micro cap | −64.16% |
| BSFA.L | BSF Enterprise Plc | $3.04M | Micro cap | −44.44% |
| CYP.AX | Cynata Therapeutics Limited | $1.92M | Micro cap | −94.88% |
| CHM.AX | Chimeric Therapeutics Limited | $659.83K | Micro cap | −95.67% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.